LRRK2 phosphorylates novel tau epitopes and promotes tauopathy

Rachel M. Bailey · Jason P. Covy · Heather L. Melrose · Linda Rousseau · Ruth Watkinson · Joshua Knight · Sarah Miles · Matthew J. Farrer · Dennis W. Dickson · Benoit I. Giasson · Jada Lewis

Abstract Mutations in the gene encoding leucine-rich repeat kinase 2 (LRRK2) are the most frequent cause of familial Parkinson’s disease (PD). The neuropathology of LRRK2-related PD is heterogeneous and can include aberrant tau phosphorylation or neurofibrillary tau pathology. Recently, LRRK2 has been shown to phosphorylate tau in vitro; however, the major epitopes phosphorylated by LRRK2 and the physiological or pathogenic consequences of these modifications in vivo are unknown. Using mass spectrometry, we identified multiple sites on recombinant tau that are phosphorylated by LRRK2 in vitro, including pT149 and pT153, which are phospho-epitopes that to date have been largely unexplored. Importantly, we demonstrate that expression of transgenic LRRK2 in a mouse model of tauopathy increased the aggregation of insoluble tau and its phosphorylation at T149, T153, T205, and S199/S202/T205 epitopes. These findings indicate that tau can be a LRRK2 substrate and that this interaction can enhance salient features of human disease.

Introduction Mutations in leucine-rich repeat kinase 2 (LRRK2) are the most frequent cause of autosomal dominant and sporadic cases of Parkinson’s disease (PD) [12, 51, 60, 78]. The functions of LRRK2 are still largely unknown (reviewed in [6]), but aberrations in its kinase activity are thought to lead to pathogenesis [3, 9, 21, 31, 33, 67, 74]. Affected carriers of LRRK2 mutations are generally clinically indistinguishable from individuals with idiopathic PD and primarily present with Lewy body pathology [3, 19, 26, 61], but neuropathology is pleomorphic and often includes hyper-phosphorylated tau protein inclusions [10, 17, 18, 43, 55, 58, 61, 71, 75].
Tau is a soluble protein that binds tubulin to promote microtubule (MT) assembly and support neuronal function (reviewed in [47]). While normal tau function is regulated by phosphorylation, certain phospho-epitopes are considered pathogenic [22] in tauopathies—neurodegenerative diseases that are characterized by the aggregation of hyperphosphorylated tau (reviewed in [68]). Tauopathies include Alzheimer’s disease (AD), progressive supranuclear palsy (PSP), Pick’s disease (PiD), and frontotemporal dementia and parkinsonism linked to chromosome-17 with mutations in the tau gene (FTDP-17t), but tau inclusions are often observed in PD brains as well (reviewed in [32]). Furthermore, tau is also present in Lewy bodies in familial and sporadic PD [14, 30]. Although FTDP-17t can result from mutations in the gene encoding tau [28, 54, 69], the cause of most tauopathies remains unknown. Given this, identifying tau kinases and determining their involvement in tau pathogenesis are vital to therapeutic targeting of tauopathies.

The appearance of hyperphosphorylated, aggregated tau in the brain of some individuals with LRRK2 mutations (reviewed in [56]) has led to the suggestion that LRRK2 may be a novel kinase for tau. Several studies, which demonstrated altered tau phosphorylation in transgenic mice expressing mutant LRRK2, support this hypothesis [40, 41, 46]. In addition, recent in vitro and cell culture studies suggest that LRRK2 may phosphorylate tau [35, 71]. If LRRK2 is a novel tau kinase, it is possible that it may phosphorylate novel tau epitopes; however, published studies have focused on a subset of the phospho-epitopes that are frequently associated with human tauopathies. Furthermore, an interaction between LRRK2 and tau has not been directly demonstrated in vivo and it is unclear if such an interaction could influence tau pathologies.

In the current report, we demonstrate that LRRK2 directly phosphorylates tau in vitro and use mass spectrometry (MS) to identify specific tau epitopes that are targets of LRRK2 in vitro. We demonstrate that LRRK2 preferentially phosphorylates tau at T149 and to a lesser extent T153—epitopes that have been largely unexplored by the tau field. We show these epitopes to be hyperphosphorylated in a range of human tauopathies and in individuals with the G2109S LRRK2 mutation using our novel antibodies. Finally, we demonstrate that human wild-type LRRK2 expression in a mouse model of tauopathy enhances tau aggregation and tau hyperphosphorylation—critical features of human tauopathy.

Materials and methods

Recombinant forms of GST-LRRK2 (970–2,527) were purchased from Invitrogen. Full-length G2019S LRRK2 was cloned into the mammalian expression vector pDEST27, expressed in HEK 293T cells and purified as previously described [8]. The human full-length tau cDNA cloned into the bacterial expression vector pRK172 was kindly provided by Dr. Michel Goedert. Recombinant full-length 0N3R tau and fragments thereof were expressed in E. coli BL21 and purified as previously described [27]. Tau mutations (E342V, P301L, P301S, and R406W) were introduced through site directed mutagenesis and verified by DNA sequencing. The mammalian expression plasmid pEF-DEST51 with the full-length wild-type (WT) (with or without a stop codon) or G2019S (with or without a stop codon) LRRK2 cDNAs to generate plasmids expressing full-length untagged LRRK2 (pEF-DEST51-LRRK2, referred to as LRRK2) or full-length LRRK2 with a C-terminal V5-tagged (pEF-DEST51-LRRK2-V5, referred to as LRRK2-V5) were previously described [72]. Synthetic tau peptides TAU-A (KKAKGADGTKIAEPRGAAPPGKQ) and TAU-B (REPKKVAVRTPPPSSAKSRL) corresponding to residues 82–105 and 163–185, respectively, in 0N3R tau, as well as threonine to alanine specific mutants were synthesized and purified on reverse phase HPLC by GenScript USA Inc. These peptide sequences correspond to residues 140–163 and 221–243, respectively in 2N4R tau. Recombinant myelin basic protein (MBP) was purchased from Millipore.

Antibodies

Anti-LRRK2 rabbit polyclonal antibody (1182) was previously described [72]. MJFF-4 (c81-8) was obtained from the Michael J. Fox Foundation. Anti-pT149 and anti-pT153 tau specific antibodies were made as a service by GenScript USA Inc. Briefly, rabbits were immunized with the pT149 peptide (DGKpTKIAEPRGAAC) or pT153 peptide (DGKTIApTPRGAAC), affinity purified with the same peptide, and negatively absorbed against the non-phosphorylated peptide (DGKTIATPRGAAC). We used polyclonal tau antibodies E1 (specific for amino acids 19–33 of human tau) [11], pT205 (Abcam), pT212 (Anaspec), pS214 (Invitrogen) [70], 17025 anti-tau (provided by Dr. Virginia Lee, University of Pennsylvania, Philadelphia, PA); and monoclonal tau antibodies CP13 (specific for pS202 in tau), PHF1 (specific for pS396/S404 in tau), and MC1 [pre-PHF conformational epitope (7–9 and 326–330)] (provided by Dr. Peter Davies, The Einstein Institute for Medical Research, Manhasset, NY, USA), AT8 (specific for pS199/pS202/pT205 in tau), AT100 (specific for pT212/S214 in tau), and AT270 (specific for pT181 in tau) (Innogenetics, Fisher Scientific). Other monoclonal antibodies used were anti-V5 (Invitrogen) and anti-GAPDH (Biodesign).
LRRK2 kinase assays

Unless otherwise noted, kinase assays were set up in a total volume of 25 μl with 25 nM recombinant GST–LRRK2 (970–2,527) in 50 mM Tris/HCl (pH 7.5), 0.1 mM EGTA, 10 mM MgCl₂, and 0.2 mM [γ-³²P] ATP (4 Ci/mmol) in the presence of 10 μM of tau or MBP substrate, unless otherwise noted. After incubation for 60 min at 30 °C, reactions were terminated by applying to individual 2.5 cm-diameter disks of P-81 phosphocellulose filter paper (Schleicher & Schuell, Keene, NH) that were immediately immersed in 75 mM phosphoric acid. After extensive washing with 75 mM phosphoric acid, P-81 filters were rinsed with acetone and allowed to air dry. Filters were immersed in Cytoscint liquid scintillation cocktail (Fisher Scientific) and ³²P radioactivity on each filter was measured by liquid scintillation using an LS6500 counter (Beckman Coulter). Kᵛ and Vₑₘₙₐₓ parameters were calculated using Graph-Pad Prism v5.02 (GraphPad Software).

For phosphorylation analysis of recombinant tau proteins with LRRK2, reactions were stopped with the addition of SDS-sample buffer and heating to 100 °C for 5 min. Samples were resolved onto SDS-polyacrylamide gels, and incorporation of phosphate was determined by autoradiography and/or immunoblotting with phospho-specific antibodies.

Mass spectrometry

As described above, 10 μM of 0N3R tau was subjected to overnight in vitro phosphorylation by either G2019S LRRK2 or the kinase dead (KD) LRRK2 mutant D1994K. Samples were resolved onto SDS-polyacrylamide gels, and then excised and washed in 50 % acetonitrile and water [5]. To maximize sequence coverage, three equivalently loaded and excised gel bands of 0N3R tau were separately digested with trypsin, chymotrypsin or GluC. Mass spectrometry (MS) analysis of modified 0N3R tau was performed as a service by the Harvard Mass Spectrometry and Proteomics Resource Laboratory (Cambridge, MA, USA). Peptide sequence analysis of each digestion mixture was performed by microcapillary reversed-phase high-performance liquid chromatography coupled with nanoelectrospray tandem mass spectrometry (μLC–MS/MS) on an LTQ-Orbitrap Velos mass spectrometer (ThermoFisher Scientific, San Jose, CA, USA). The Orbitrap repetitively surveyed an m/z range from 395 to 1,600, while data-dependent MS/MS spectra on the twenty most abundant ions in each survey scan were acquired in the linear ion trap. MS/MS spectra were acquired with relative collision energy of 30 %, 2.5-Da isolation width, and recurring ions dynamically excluded for 60 s. Preliminary sequencing of peptides was facilitated with the SEQUEST algorithm [15] with a 30 ppm mass tolerance against the human subset of the Uniprot Knowledgebase supplemented with a database of common laboratory contaminants, concatenated to a reverse reverse decoy database. Using a custom version of Proteomics Browser Suite (PBS v.2.7, ThermoFisher Scientific, San Jose, CA, USA) peptide-spectrum matches (PSMs) were accepted with mass error <2.5 ppm and score thresholds to attain an estimated false discovery rate of ~1 %. Data-sets for all digest results were combined in silico, culled of minor contaminant PSMs, and researched with SEQUEST algorithm against the 0N3R tau sequence without taking into account enzyme specificity and with differential modifications of phosphorylated tyrosine, serine, and threonine residues. The discovery of phosphopeptides and subsequent manual confirmation of their MS/MS spectra were facilitated using in-house versions of programs MuQuest, GraphMod, and FuzzyIons (PBS, ThermoFisher Scientific).

Enzyme-linked immuno sorbent assay (ELISA) to assess antibody specificity

Recombinant C-terminal fragment of human 3R tau [C′ Tau] corresponding to amino acids 244–441 minus amino acids 275–305 that would be present in 2N4R tau human tau was phosphorylated with recombinant glycogen synthase kinase 3 beta (GSK-3β) (New England BioLabs Inc, Ipswich, MA, USA) (20 mM Tris, pH 7.5, 10 mM MgCl₂, 5 mM DTT, 200 μM ATP, 1 mg/ml tau and 20,000 units enzyme in 50 μl) for 1 h at 30 °C. Controls included similar reactions without the kinase. 100 ng of each synthetic peptide or 500 ng of tau recombinant protein diluted in 100 μl of water was absorbed per well of 96-well EIA/RIA Corning plates (Corning, NY, USA). The plates were extensively washed with PBS and blocked with PBS/5 % fetal bovine serum (FBS). Primary antibodies as indicated were diluted in PBS/5 % FBS and incubated on the plates. After extensive washes with PBS, plates were incubated with either anti-mouse antibody conjugated to HRP or anti-rabbit antibody conjugated to HRP diluted in PBS/5 % FBS. Plates were again extensively washed with PBS and reactions were carried out with 3,3′,5,5′-tetramethylbenzidine (TMS) reagents (KPL, Gaithersburg, NY, USA). The reactions were terminated by adding 0.2 M HCl and optical density was measured at OD₄₅₀ using a Multiskan Plus plate reader (ThermoFisher). Experiments were performed in quadruplicate.

Cell culture

HEK 293T cells were cultured in Dulbecco’s modified medium with high glucose (4.5 g/l) supplemented with
10 % FBS, 100 U/ml penicillin, 100 U/ml streptomycin, and 2 mM L-glutamine. Cells were plated onto 6-well plates and transfected at approximately 30 % confluence using Lipofectamine 2000 according to the manufacturer’s protocol. Cells were maintained for 48 h after transfection. Cells were harvested and lysed in 3 % SDS/50 mM Tris–HCl, pH 6.8 and heated to 100 °C for 5 min. Protein concentration was determined using BCA protein assay reagent and BSA as the standard (Pierce, Fisher Scientific). Experiments were performed in duplicate.

Mice

Mice were housed and treated in accordance with the NIH Guide for the Care and Use of Laboratory Animals. All animal procedures were approved and conducted in accordance with the Mayo Clinic Institutional Animal Care and Use committee and the University of Florida Institutional Animal Care and Use committee. Mice were maintained in a pathogen-free facility on a 12 h light/dark cycle with water and food provided ad libitum.

The parental TauP301l responder line and parental tTA activator line were generated and maintained on an FVB and 129/S6 background, respectively, as previously described [65]. Bigenic rTg4510 mice have forebrain-focused expression of P301l transgenic tau. The parental bacterial artificial chromosome (BAC)-lrrK2 mouse line for one generation to obtain the resultant F1 lrrK2.TauP301l responder mice on a 50 % FVB, 50 % 129S background, the same as the original rTg4510 mouse model [65]. All mice in this study were harvested at 5.5 months of age when mature cortical tangles and hippocampal neurodegeneration are detectable in TauP301l only animals. We harvested 10 mice per group, half male and half female, for the four genotypes of interest (non-transgenic, LRRK2, TauP301l, and LRRK2/TauP301l). One male LRRK2/ TauP301l mouse did not overexpress LRRK2 (as determined by western blotting) and was excluded from all studies. The sarkosyl-preparation (see protocol below) of one female TauP301l mouse had extremely high tau aggregation via western blotting and was identified by Grubb’s analysis to be an outlier. As this may have been a tissue preparation error, all western blot data from this mouse were excluded from the final results.

Tissue harvest and preparation

All mice were euthanized by cervical dislocation to maintain the brain biochemistry by avoiding anesthesia-induced tau changes. Brains were quickly removed, cut down the midline, and one brain half was drop fixed in 10 % formalin for 24 h for immunohistochemical analysis and the other brain half was immediately homogenized to preserve the LRRK2 protein. Brains were homogenized in 6 volumes of homogenate buffer [50 mM Tris–HCl, pH 8.0, 274 mM NaCl, 5 mM KCl, 1 % protease inhibitor mixture (Sigma), 1 % phosphatase inhibitor cocktails I and II (Sigma), and 1 mM phenylmethylsulfonyl fluoride (PMSF)]. For LRRK2 analysis, homogenates were centrifuged at 150,000×g for 15 min at 4 °C. The supernatants were collected and protein concentration was determined using BCA protein assay reagent and BSA as the standard. For tau analysis, the brain homogenate was diluted in 10 volumes using Tris-buffered saline and subjected to sarkosyl fractionation as previously described [65]. Specifically, 200 μl of 10× homogenate was centrifuged at 150,000×g for 15 min at 4 °C and the supernatant, which contains soluble tau species, was collected and protein concentration was determined as described above. Pellets were homogenized in 3 volumes (600 μl) of Buffer B [10 mM Tris–HCl (pH 7.4), 0.8 M NaCl, 10 % Sucrose, 1 mM EGTA and 1 mM PMSF] and centrifuged at 150,000×g for 15 min at 4 °C. The supernatants were collected and incubated with 1 % sarkosyl (Sigma) for 1 h at 37 °C, followed by centrifugation at 150,000×g for 30 min at 4 °C to obtain a sarkosyl-soluble supernatant and sarkosyl-insoluble pellet. The sarkosyl-insoluble pellet, which contains the biochemical equivalent of neurofibrillary tangles, was re-suspended in 20 μl TE buffer [10 mM Tris–HCl (pH 8.0), 1 mM EDTA].

Western blot analysis

For in vitro and cell culture experiments, equal amounts of protein samples were loaded and resolved by SDS-PAGE, followed by electrophoretic transfer onto nitrocellulose membranes. Membranes were blocked in Tris-buffered saline (TBS) with 5 % non-fat milk powder, and incubated overnight with 1182 LRRK2-specific antibody [72], anti-V5 antibody (Invitrogen), or anti-tau antibody (17025) in TBS/5 % non-fat milk powder. Membranes were also incubated overnight with pTI49 or pTI153 tau specific antibodies in TBS/5 % BSA. Each incubation was followed by goat anti-mouse conjugated horseradish peroxidase (HRP) (Amersham Biosciences) or goat anti-rabbit HRP (Cell Signaling Technology), and immunoreactivity was detected using chemiluminescent reagent (NEN) followed by exposure on X-ray film.
For analysis of LRRK2 protein in mouse brain tissue, 50 μg of protein was diluted in NuPAGE LDS-sample buffer with NuPAGE reducing agent (Invitrogen), boiled for 3 min at 95 °C, loaded onto 26-well 3–8 % Tris–glycine gels (Invitrogen), separated by SDS-PAGE and transferred in NuPAGE transfer buffer (Invitrogen) to PVDF membranes (Millipore, Fisher Scientific). Membranes were blocked for 1 h at room temperature in 5 % non-fat milk powder in TBS with 0.1 % Triton X-100 (TBS-T) and then incubated overnight in primary antibody diluted in 5 % non-fat milk powder in TBS-T at 4 °C. For tau protein analysis from mouse brain, 5 μg of the soluble fraction or 3 μl of the sarkosyl-insoluble fraction was diluted in Novex Tris–glycine SDS-sample buffer (Invitrogen) with β-mercaptoethanol, heat denatured at 95 °C for 5 min, loaded onto 26-well 10 % Tris–glycine gels (Invitrogen), separated by SDS-PAGE and transferred in CAPS transfer buffer (Sigma) to PVDF membranes. Membranes were blocked in TBS-T with 5 % non-fat milk powder and incubated overnight with antibody in TBS-T/5 % non-fat milk powder, except for pT149 and pT153 tau antibodies, which were in TBS-T/5 % BSA. All membranes were washed 3 times in TBS-T, incubated with either goat anti-mouse HRP or goat anti-rabbit HRP secondary antibodies (Jackson ImmunoResearch) for 1 h at room temperature and washed again 3 times in TBS-T. Membranes were developed using Western Lightning Plus (Perkin Elmer) and imaged using a FluorChem E System (ProteinSimple). The relative levels of immunoreactivity were determined by densitometry using the software AlphaView SA (ProteinSimple).

Immunohistochemistry

Fixed mouse brains were paraffin embedded and cut into 5 μm sagittal sections. Hematoxylin and eosin (H&E) staining was performed on at least two brain sections from each mouse to align all brains to approximately 1.3 mm lateral to the midline using a mouse brain atlas [52]. Immunohistochemistry with the Dako Universal Autostainer with DAKO Envision + HRP system (Dako) was performed with the following antibodies: pT149 tau, pT153 tau, AT8, AT270, CP13, and MC1. Stained slides were digitally scanned using a ScanScope XT scanner and were analyzed using ImageScope version 11.2.0.780 software (Aperio). Positive pixel count algorithms were created to measure the staining density of the secondary antibody, specifically chromogen 3,3′ dianinobenzidine. The cortex of each animal was traced and analyzed using these algorithms and the burden was expressed as a percentage of immunostained pixels to total area. Sections that had tears or other artifacts were not included in the analysis.

Paraffin embedded sections were processed for immunohistochemistry as above for mice from 3R + 4R tauopathy (5 AD—average age: 90 ± 6 years; 4 women; median Braak NFT Stage: VI; 2 with concurrent diffuse cortical Lewy bodies), 4R tauopathy (4 PSP and 1 CBD—average age: 77 ± 7 years; 4 women; median Braak NFT Stage: III), 3R tauopathy (2 PiD—average age: 68 ± 6 years; 1 woman; median Braak NFT Stage: III), and mutant LRRK2 carriers (4 G2019S—average age: 76 ± 5 years; 2 women; Braak NFT Stage: 0–V). Sections were counterstained with hematoxylin.

Statistical analysis

Grubb’s analysis was used to identify outliers in the western blot analysis of sarkosyl-insoluble tau. Data are presented as the mean ± standard error mean unless otherwise noted. Analysis of two groups was performed with an unpaired, two-tailed Student’s t test while analysis of multiple groups was analyzed by one-way ANOVA and post hoc Bonferroni multiple comparisons test (α = 0.05). Western blot and immunohistochemical data from male and female TauP301L and LRRK2/TauP301L mice were analyzed by two-way ANOVA with genotype and sex as independent variables. All analyses were performed using GraphPad Prism version 6.00 software (GraphPad Software) and in all cases, P ≤ 0.05 was considered to be statistically significant.

Human tissue

Wild-type and mutant LRRK2 phosphorylates multiple tau isoforms in vitro

To determine if LRRK2 directly phosphorylates tau, recombinant tau (2N4R) was incubated with multiple forms of recombinant GST-LRRK2 (970–2,527) and incorporation of γ-[32P] ATP was determined by autoradiography. Both wild-type (WT) and mutant (G2019S, I2020T and R1441C) LRRK2 phosphorylated recombinant tau in vitro (Fig. 1a). Although we analyzed three different LRRK2 mutants, each of which has been implicated in familial PD with neurofibrillary tangle pathology, G2019S LRRK2 yielded the highest level of tau phosphorylation. Further, tau phosphorylation was largely ablated when using the LRRK2 kinase dead/impaired (KD) D1994K mutant (Fig. 1a), indicating that LRRK2 directly phosphorylated tau in vitro. We then examined the ability of mutant LRRK2 to phosphorylate different tau isoforms that contain alternatively spliced N-terminal (0, 1 or 2 N) and C-terminal MT-binding domains (3R or 4R). Recombinant GST-G2019S LRRK2
phosphorylated all forms of tau regardless of isoform or the presence of FTDP-17-associated mutations (e342V, P301L, P301S and R406W) (Fig. 1b). These findings were confirmed using full-length g2019S lrrK2 (Supplemental Fig. 1).

Identification and characterization of tau residues phosphorylated by lrrK2 in vitro

To identify the tau residues that are phosphorylated by LRRK2 in vitro, we performed MS analyses of tau (0N3R) phosphorylated with gST-g2019S lrrK2 (970–2,527). Using the shortest tau isoform with the highest kinase active lrrK2, we had the greatest likelihood of complete coverage. We obtained >99% sequence coverage from the 0N3r isoform and identified multiple tau residues phosphorylated by g2019S lrrK2 (Fig. 2a), with T149, T153, T169, T205, T263 and T231 identified as the major phosphorylation sites by lrrK2 (Supplemental Table 1). These modifications were not present in identical MS analysis of 0N3r tau incubated with KD lrrK2. To parse the sites that were preferentially phosphorylated by lrrK2, we incubated various forms of recombinant LRRK2 with synthetic peptides that spanned short regions of tau containing 1–3 potential tau phospho-epitopes (Supplemental Table 2) and quantified the resultant phosphorylation. G2019S-LRRK2 showed the greatest phosphorylation of the Tau-A (KKAKGADGTKKIAATPGRAGAPPQK) and Tau-B (REP-KKAVVRTPPKPSSSAKSLR) peptides, with the WT Tau-B peptide phosphorylated 83 ± 1.7 % (P < 0.001) less than the WT Tau-A peptide (Fig. 2b) as assessed by one-way ANOVA and post hoc Bonferroni multiple comparisons test. The other peptides demonstrated minimal phosphorylation. These data were consistent with the MS data, which showed that pT149 and pT153 peptides were among the most abundant phosphorylated products resulting from LRRK2-mediated tau phosphorylation. Alanine substitution to block site-specific LRRK2 phosphorylation of the Tau-A peptide reduced phosphorylation by 93 ± 1.2 % (T149A; P < 0.0001) and 21 ± 1.2 % (T153A; P < 0.001) compared to WT Tau-A (Fig. 2b), indicating that tau T149 and T153 were primary and secondary targets, respectively, of LRRK2-directed phosphorylation. We then assessed the kinetic features of WT and G2019S LRRK2 phosphorylation of Tau-A (see “Materials and methods”) where the concentration of Tau-A was varied as indicated while the concentration of ATP was constant at 200 μM. The $K_m$ of WT and G2019S LRRK2 for the Tau-A peptide was determined to be ~170 μM, which is similar to that of lrrK-tide, the most robust and commonly used LRRK2 substrate in kinetic studies [1, 9, 31, 48]. Furthermore, like LRRK-tide, the $V_{max}$ of tau phosphorylation by G2019S LRRK2 was ~threefold greater than that of WT LRRK2 (Fig. 2c) [9].

Tau is phosphorylated at T149 and T153 in G2019S carriers and in a range of human tauopathies

To assess phosphorylation of tau T149 or T153, we created antibodies specific for each phospho-epitope (see “Materials and methods”). ELISA analysis of pT149 and pT153 tau antibodies was used to establish the phospho-specificity of each antibody. Results showed that both antibodies are highly specific for tau peptides phosphorylated at their respective epitopes with minimal reactivity to non-phosphorylated tau peptide, non-phosphorylated C-terminal tau [C′ Tau] and C′ Tau phosphorylated by GSK-3β (Fig. 3a). In addition, pT149 antibody had minimal cross reactivity to tau peptide phosphorylated at T153 and the pT153 antibody had low cross reactivity to tau peptide phosphorylated at T149, but none when compared to the other control peptides. Both pT149 and pT153 antibodies recognized
tau that had been incubated with GST-G2019S LRRK2 (970–2,527), but not with GST-KD LRRK2 (970–2,527) (Fig. 3b). Further, HEK 293T cells were co-transfected with expression plasmids for 2N4r tau and pcDNA3.1, untagged full-length WT or G2019S LRRK2, or V5-tagged full-length WT or G2019S LRRK2. Immunoblot analysis of cell lysates with total tau and pT149 tau antibodies confirmed that both tagged and untagged full-length WT and G2019S LRRK2 increased phosphorylation of tau at T149 in vivo by 8.4 ± 0.8-fold more (WT; P < 0.0001) and 7.5 ± 0.4-fold more (G2019S; P < 0.0001) than vector transfected control cells when normalized to total tau (Fig. 3c).

To test the pathological relevance of pT149 and pT153, we performed immunohistochemistry on brain tissue from different human tauopathies using our pT149 and pT153 tau antibodies. Both antibodies recognized neurofibrillary pathology in AD (Fig. 3d, left panels), including neurofibrillary tangles, neuropil threads and dystrophic neurites in senile plaques. Further, both antibodies stained pathological tau in patients with the g2019S LRRK2 mutation (Fig. 3d, right panels). In addition to the tangle pathology previously reported for

---

**Fig. 2** LRRK2 phosphorylates multiple tau epitopes in vitro. a Highlighted amino acids indicate residues of 0N3R tau phosphorylated by GST-G2019S LRRK2 (970–2,527), but not by kinase dead GST-LRRK2 (970–2,527) as identified as putative sites by mass spectrometry. We obtained coverage of ~99 % of the 0N3R construct as indicated by capital letters. Major phosphorylation sites are highlighted in black. The entire amino acid sequence for the longest human tau isoform, 2N4R, is denoted and the tau domains, encoded by the alternatively spliced exons 2, 3, and 10 that were not included in the 0N3R tau construct are boxed. b We compared GST-G2019S LRRK2 (970–2,527) phosphorylation using synthetic peptides (Tau-A and Tau-B) as indicated by blue underlines in a. The degree of G2019S LRRK2-directed phosphorylation of WT Tau-A (T149, T153) and Tau-B (T231) peptides was compared to Tau-A and Tau-B with individual alanine mutants (T149A, T153A, T231A), which blocked phosphorylation at each residue, to determine the relative substrate potential of each epitope. c Kinetics of GST-WT and -G2019S LRRK2 (970–2,527) phosphorylation of Tau-A peptide. The concentration of Tau-A substrate was varied as indicated while the concentration of ATP was constant at 200 μM
G2019S mutant carriers, our antibodies identified tau surrounding Lewy bodies in the brainstem (Fig. 3e). These results indicate that in addition to G2019S-LRRK2 carriers, tau hyperphosphorylation at T149 and T153 occurs in a range of human tauopathies, including so-called 4R-tauopathies, 3R-tauopathies and 3R + 4R tauopathies, and that phosphorylation of these epitopes is linked to pathology, since no staining was detected in unaffected brains or unaffected brain regions in tauopathies (data not shown).

LRRK2 does not alter levels or phosphorylation of soluble tau in LRRK2/TauP301L mice

To determine, if LRRK2 could modify the development of tauopathy in vivo, we crossed human WT LRRK2
BAC mice that do not have an overt phenotype or pathological abnormalities (including evidence of tau pathology) [46], with rTg4510 mice that express human mutant (P301L) 0N4R tau [65] to generate mice that expressed both transgenes (LRRK2/TauP301L) (see breeding scheme in Supplemental Fig. 2). LRRK2 BAC mice showed the highest expression of transgenic LRRK2 in the hippocampus as well as high expression in the cortex [46]. These regions overlap well with the forebrain-focused transgenic tau expression that is conditionally driven by a CAMKIIα-tTA transgene in the rTg4510 mice [65], reducing the likelihood that an interaction between the proteins would be missed due to disparate expression profiles. The forebrain of 5.5-month-old rTg4510 mice, hereafter termed TauP301L, has been shown previously to have insoluble hyperphosphorylated tau, neurofibrillary tangles, and neuronal loss [59, 65]. We, therefore, examined LRRK2/TauP301L mice at 5.5 months of age for alterations in this well-characterized pathology.

Initially, we confirmed that all LRRK2/TauP301L experimental mice expressed the LRRK2 (Fig. 4a, b) and tau (Fig. 4c, d) transgenes. Soluble tau fractions typically contain normal tau species that run at ~55 kDa which can be used to determine equal levels of expression across mice.

Human LRRK2 expression in LRRK2/TauP301L mice did not affect human tau levels in the normal (soluble) fraction (Fig. 4c, d) when compared to TauP301L mice alone, ensuring that any effects on tauopathy in the LRRK2/TauP301L mice would not be due to expression artifact. With a panel of phospho-specific tau antibodies, we then analyzed soluble tau via western blotting for phosphorylation at sites that we confirmed to be directly phosphorylated by LRRK2 in vitro (T149 and T153) and/or identified by our initial MS results (T181, T212 and T205). We also included epitopes that are associated with human disease and were not identified by our MS analysis (S202, S214, and S396/S404).

We did not detect any changes in the phosphorylation of the ~55 kDa soluble tau in LRRK2/TauP301L mice when compared to the TauP301L mice with any antibody utilized (Supplemental Fig. 3). We and others have previously reported that species of higher molecular weight tau can be observed in the soluble fraction, potentially representing some species of aggregated tau [39, 63, 64]. Interestingly, our pT153 antibody recognized a ~64 kDa band in the soluble fraction of both TauP301L and LRRK2/TauP301L mice (Supplemental Fig. 3a). Comparison of this band between both cohorts (P = 0.17) failed, however, to reach our 0.05 threshold for significance.

Accumulation and phosphorylation of insoluble tau is increased in LRRK2/TauP301L mice

An important feature of human tauopathy and a subset of mutant LRRK2 carriers is the aggregation of tau. In tauopathies, tau aggregation is associated with the shift of tau into the biochemically abnormal, sarkosyl-insoluble fraction. We, therefore, examined the sarkosyl-insoluble fractions of brains from LRRK2/TauP301L mice by western blot analysis to determine if LRRK2 enhances tau aggregation compared to TauP301L mice. Using the phospho-independent, human tau antibody, E1, we found that insoluble, aggregated tau levels were ~3.5 times higher in LRRK2/TauP301L compared to TauP301L mice (Fig. 5a, b). Insoluble tau from both LRRK2/TauP301L and TauP301L mice migrated primarily as a ~64 kDa band—a species that we have previously shown to correlate with the presence of NFTs in tau transgenic mice [39]. Using a two-way ANOVA (genotype × sex), we then determined that the levels of sarkosyl-insoluble human tau in TauP301L and LRRK2/TauP301L mice were affected by both genotype [F(1, 14) = 34, P < 0.0001] and sex [F(1, 14) = 34, P < 0.0001], and that there was also a significant interaction between both factors [F(1, 14) = 14, P < 0.01]. To help interpret these findings, we analyzed females and males separately and found that female LRRK2/TauP301L mice had approximately 3.6 times more insoluble tau compared to female TauP301L mice (P < 0.001) (Supplemental Fig. 4a), and that male LRRK2/TauP301L mice had 2.8
times more insoluble tau compare to male Tau P301l mice ($P < 0.05$) (Supplemental Fig. 4b). We then analyzed the sarkosyl-insoluble fraction of TauP301l and lrrK2/Tau P301l mouse brains using our panel of phospho-tau antibodies and found that lrrK2 increased phosphorylation of insoluble tau at all epitopes that were examined (Supplemental Figs. 5 and 6). To determine if the elevated levels of phosphorylated tau were simply driven by the overall increase of aggregated tau in the insoluble fraction, we normalized the densitometry of each phospho-tau antibody by the densitometry of sarkosyl-insoluble human tau for each mouse. When normalized for the amount of insoluble tau in the sarkosyl-insoluble fraction, analysis by two-way ANOVA (genotype × sex) revealed a main genotype effect with increased phosphorylation of T149, T205, and S199/S202/T205 (Fig. 5c, g, h; Table 1) and decreased phosphorylation of T181 in lrrK2/Tau P301l mice compared to Tau P301l mice (Fig. 5e; Table 1). Phosphorylation of T153 in lrrK2/Tau P301l mice compared to Tau P301l mice ($P = 0.07$) did not reach our significance threshold (Fig. 5d; Table 1) and phosphorylation of S202, T212, S214, T212/S214 and S396/S404 was unchanged by co-expression of lrrK2 in Tau P301l mice (S202: $P = 0.62$; T212: $P = 0.32$; S214: $P = 0.90$; T212/S214: $P = 0.63$; and S396/S404: $P = 0.40$) (Fig. 5f, i–l; Table 1). In addition, this analysis revealed a main sex effect for pT181 (AT270), S199/S202/T205 (AT8) and S396/S404 (PHF1), but not the other epitopes examined (see statistical summary in Table 1).

**LRRK2/TauP301l mice have enhanced cortical tau pathology**

We sought to validate our biochemical studies with neuropathological analysis of tau burden using antibodies that detect specific phosphorylation or conformational tau epitopes. All antibodies identified prominent tau pathology, including neurofibrillary tangles, in the brains of TauP301l and LRRK2/TauP301l mice, which was absent in the LRRK2 only transgenic and non-transgenic (nTg) mice (Fig. 6). Tau pathology was distributed throughout the cortex and hippocampus of TauP301l and LRRK2/TauP301l mice; however, we focused our assessment on the cortex since neuronal loss within the hippocampus can confound accurate assessment of tau burden at this age. Using two-way ANOVA analysis, we observed significant increases in phosphorylated tau pathology in LRRK2/TauP301l mice with pT149, pT153, CP13, and AT8 immunostaining when
Fig. 5 LRRK2/TauP301L mice have elevated insoluble, hyperphosphorylated tau compared to TauP301L. Western blot analyses of the sarkosyl-insoluble fractions of whole brain lysates from TauP301L only and LRRK2/ TauP301L mice. a Representative immunoblot probed with an antibody (E1) that recognizes human tau, regardless of phosphorylation state, shows significantly more aggregated (insoluble) human tau in LRRK2/ TauP301L compared to TauP301L only mice as measured by (b) densitometry. Note the ~64 kDa species of tau (a) that we have previously shown to be a highly aggregated, hyperphosphorylated form of 0N4R tau [64]. c–l Levels of insoluble tau phosphorylated at T149 (c), T153 (d), T181 (AT270) (e), S202 (CP13) (f), T205 (g), S199/S202/T205 (AT8) (h), T212 (i), S214 (j), T212/S214 (AT100) (k), and S396/S404 (PHF1) (l), as measured by densitometry (Supplemental Fig. 6), were adjusted by levels of human tau in the insoluble fraction (a-b) to distinguish specific phosphoepitopes that are enriched in the insoluble fraction. Phosphorylation of insoluble tau is increased at T149, T205 and S199/S202/T205 and decreased at T181 when normalized to the amount of tau in the sarkosyl-insoluble fraction. Each dot represents an individual mouse with the mean indicated by the black line, n = 9 per cohort. *P ≤ 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 [two-way ANOVA (genotype × sex): main effect of genotype indicated]. Summary of two-way ANOVA found in Table 1.
compared to Tau<sub>P301L</sub> mice (Figs. 6, 7; Table 1). Although the burden of tau pathology with these antibodies was also significantly influenced by sex, where females had greater burden than males, there was no interaction between the genotype and sex (Fig. 7; Table 1). In addition, we observed significant increases in conformationally-abnormal tau in LRRK2/Tau<sub>P301L</sub> mice with MC1 immunostaining when compared to Tau<sub>P301L</sub> mice (Figs. 6, 7; Table 1). Tau burden as assessed with MC1 was also significantly influenced by sex, but there was no interaction between genotype and sex (Table 1). No significant difference in tau burden was observed with AT270, irrespective of genotype or sex (Figs. 6, 7; Table 1).

**Discussion**

In the current study, we combined in vitro, cell culture, and novel transgenic studies to demonstrate that tau is a substrate of LRRK2 and that this interaction promotes tauopathy. We found that recombinant WT and mutant LRRK2 directly phosphorylates tau in kinase assays. As shown previously for other LRRK2 substrates, G2019S LRRK2 yields the greatest levels of tau phosphorylation [9, 21, 31, 74]. Our subsequent in vitro studies used G2019S LRRK2 to obtain the highest levels of substrate phosphorylation, thereby reducing the chance that LRRK2-directed phosphorylation of tau would be inadvertently missed. Using MS analysis, we uncovered the tau epitopes that were potentially targeted by LRRK2 phosphorylation. To reduce false positives, MS analysis was performed in parallel with reactions utilizing KD LRRK2, and we further validated subsequent hits using LRRK2 kinase reactions coupled with site directed mutagenesis at identified sites of phosphorylation to block LRRK2 activity. Surprisingly, we identified tau T149 and T153 as a preferential target and a secondary target, respectively, of LRRK2-directed phosphorylation. Although much of our studies focused on mutant LRRK2, we sought to determine if tau could be a substrate of LRRK2 in vivo by generating novel transgenic mice, which expressed human WT LRRK2 and mutant tau. WT LRRK2 mice alone do not develop tau abnormalities and the tau abnormalities observed in mutant LRRK2 mice are modest [40, 41, 46]. For our LRRK2/Tau<sub>P301L</sub> model, we combined a WT LRRK2 BAC line [46] with a Tau<sub>P301L</sub> (rTg4510) model [65]. The

---

**Table 1** Summary of sarkosyl-insoluble and immunohistochemical analysis of tau measured from female and male Tau<sub>P301L</sub> and LRRK2/Tau<sub>P301L</sub> mice

| Stain | Genotype | Sex | Interaction |
|-------|----------|-----|-------------|
|       | F(DFn, DFd) | P value | F(DFn, DFd) | P value | F(DFn, DFd) | P value |
| pT149 | (1, 14) = 15 | P < 0.005 | (1, 14) = 0.99 | P = 0.97 | (1, 14) = 0.01 | P = 0.92 |
| pT153 | (1, 14) = 3.8 | P = 0.07 | (1, 14) = 1.0 | P = 0.33 | (1, 14) = 0.16 | P = 0.70 |
| AT270 | (1, 14) = 7.73 | P ≤ 0.05 | (1, 14) = 33.44 | P < 0.0001 | (1, 14) = 0.66 | P = 0.43 |
| CP13  | (1, 14) = 0.25 | P = 0.62 | (1, 14) = 1.59 | P = 0.23 | (1, 14) = 4.47 | P ≤ 0.05 |
| pT205 | (1, 14) = 5.4 | P ≤ 0.05 | (1, 14) = 1.9 | P = 0.19 | (1, 14) = 0.01 | P = 0.92 |
| AT8   | (1, 14) = 24 | P < 0.0005 | (1, 14) = 64 | P < 0.0001 | (1, 14) = 8.5 | P ≤ 0.05 |
| pT212 | (1, 14) = 1.05 | P = 0.32 | (1, 14) = 0.03 | P = 0.87 | (1, 14) = 0.12 | P = 0.74 |
| pS214 | (1, 14) = 0.02 | P = 0.90 | (1, 14) = 0.07 | P = 0.79 | (1, 14) = 2.17 | P = 0.16 |
| AT100 | (1, 14) = 0.25 | P = 0.63 | (1, 14) = 1.49 | P = 0.24 | (1, 14) = 4.89 | P = 0.04 |
| PHF1  | (1, 14) = 0.76 | P = 0.40 | (1, 14) = 11.63 | P < 0.005 | (1, 14) = 4.14 | P = 0.06 |

*Top* statistical results from a two-way ANOVA (genotype × sex) of the densitometry of phospho-specific tau antibodies normalized to the amount of human tau in the insoluble fraction for each mouse. *Bottom* Statistical results from a two-way ANOVA (genotype × sex) of cortical staining with phospho- and conformational-specific tau antibodies.

© Springer
rTg4510 model represents a well-characterized model, providing a “primed system” in which we could determine if human LRRK2 phosphorylates tau in vivo and if this could influence the development of tauopathy. We demonstrated that human WT LRRK2 expression in a mouse model of tauopathy enhances tau aggregation and tau hyperphosphorylation—critical features of human tauopathy.

Having identified T149 and T153 on tau as primary targets of direct G2019S LRRK2 phosphorylation in vitro, we then sought to determine the relevance of these sites to human tauopathy. One study has reported that T149 tau is phosphorylated by recombinant CK1δ and gSK-3β kinases [23]; however, phosphorylation of T149 has not been studied in vivo or associated with disease. Phosphorylation of T153 has been described in vitro and in cell culture [23, 29, 66] and one study shows that phospho-T153 (pT153) antibody labels neurofibrillary tangles in AD brain [2]. It is still unknown to what extent phosphorylation of T153 is associated with other tauopathies. We created antibodies specific for tau phosphorylated at T149 and at T153, respectively (see “Materials and methods”). We then confirmed their specificity in vitro and in cell culture and demonstrated the presence of these phospho-epitopes in neuronal and glial lesions of 3R tauopathies (PiD), 4R tauopathies (PSP) and 3R + 4R tauopathies (AD) and in G2019S-LRRK2 carriers (PD). There was also immunoreactivity in a subset of Lewy bodies, similar to the pattern we previously noted with other antibodies to phospho-tau [30]. T149 and T153 are largely unexplored tau epitopes, but it is of interest that they flank a rare variant in tau, A152T, that may be a risk factor for tauopathies such as PSP [7, 34, 36]. LRRK2 is not known to play a role in tauopathies beyond its involvement in PD, but it is possible that rare genetic variants in LRRK2, including those that confer risk to PD [16, 60, 62] or have yet to be uncovered, could play a role in tauopathies. The pT149 and pT153 immunostaining in these diverse cases of human tauopathy suggests that further studies on the role of LRRK2 in these disorders could be informative.
No changes to tau levels or phosphorylation were observed in the soluble fraction of LRRK2/TauP301L mice compared to TauP301L mice. Initial analysis of the insoluble fraction revealed increased phosphorylation of all epitopes examined in LRRK2/TauP301L mice. This was not surprising, however, as there was approximately three times more tau in the insoluble fraction of LRRK2/TauP301L mice. To account for the significant difference of insoluble tau in TauP301L only and LRRK2/TauP301L mice, it was necessary to adjust the phospho-tau levels to the total amount of insoluble tau present to fully assess if there were specific phosphorylation changes associated with LRRK2 overexpression. We found that co-expression of LRRK2 in TauP301L mice selectively increased insoluble tau phosphorylation at sites identified in vitro as being directly phosphorylated by LRRK2, T149 and T153, as well as the T205 and S199/S202/T205 epitopes. Interestingly, our in vitro results were performed in the context of soluble tau; whereas, the elevated phosphorylation in the mice in the presence of LRRK2 was only in insoluble tau. These data suggest that LRRK2-associated phosphorylation may be able to trigger the shift of soluble tau into the insoluble fraction. Davies et al. [13] have isolated a substantial amount of LRRK2 in the insoluble protein fraction using a Triton and SDS preparation and demonstrated that LRRK2 is not exclusively soluble in WT rodents or in humans. This could support a potential interaction of LRRK2 and tau in LRRK2/TauP301L mice as tau switches from its highly soluble (normal) state to the insoluble protein that is found in tauopathy. Alternatively, filamentous tau may be a better substrate for LRRK2 compared to the soluble tau. Neuropathological analysis revealed increased tau burden using antibodies for tau phosphorylated at T149, T153, S202, and pS199/S202/T205, largely replicating what we observed in our biochemical analysis. By both biochemical and histological analyses enhanced phosphorylation was detected by the AT8 antibody that recognizes a triple epitope (pS199/S202/S205). It is possible that these findings are due to increased phosphorylation at S202 or T205 that was observed with antibodies that specifically detect those singular epitopes.

Our in vitro and in vivo findings support that T149 tau is the primary target of direct LRRK2 phosphorylation and suggests that T153 may be a secondary target. Our MS studies identified T205 as a potential LRRK2 phosphorylation site which was not validated in our subsequent in vitro work utilizing synthetic peptides for this region; therefore, the increased phosphorylation of insoluble tau at T205 and the combined S199/S202/T205 epitope, recognized by the AT8 antibody, may indicate an indirect mechanism by which LRRK2 increases phosphorylation of these specific tau epitopes in vivo. Alternatively, phosphorylation of T205 may require unique modeling of secondary and tertiary structure, and therefore be a better substrate for LRRK2 in vivo than it is in vitro. In addition, microtubules or other co-factors may act as scaffold to bring tau and LRRK2 together, allowing LRRK2 to phosphorylate tau at additional epitopes [35]. LRRK2 might also directly phosphorylate other tau kinases and enhance their ability to target tau [49, 76], including AKT, GSK-3β, and members of the MAPK family, which have been implicated downstream of LRRK2 activity [4, 20, 42, 44, 53, 57]. In addition, LRRK2 phosphorylation of its main target epitopes (i.e., T149) may have the ability to enhance phosphorylation of additional epitopes by other tau kinases; such cooperation has been noted with other phospho-tau epitopes [45, 77]. Further experiments examining the interaction between LRRK2-associated tau phosphorylation and tau phosphorylation by known tau kinases are required to test this.

For proteins that are highly phosphorylated, such as tau, it is common to find redundancy of phosphorylation of a given residue by multiple kinases. For example, S202 tau has been shown to be phosphorylated by at least 8 different kinases, including CK1 (reviewed in [37]). CK1δ has also been shown to phosphorylate T149 tau in vitro [23] and interestingly, both CK1δ and LRRK2 have been shown to phosphorylate the disease-related α-synuclein protein at S129 [50, 57]. Given this, it would not be surprising if both kinases could phosphorylate tau at the same epitope. In Drosophila, LRRK2 has been proposed to increase tau phosphorylation at T212 in a GSK-3β dependent manner [42]. In our LRRK2/TauP301L mice, we did not detect increased phosphorylation of tau at T212 nor at S396/S404, a second epitope phosphorylated by GSK-3β [38], indicating that LRRK2 expression in TauP301L mice did not ubiquitously increase phosphorylation of tau epitopes targeted by GSK-3β (reviewed in [24]). Surprisingly, we observed a significant decrease in phosphorylation of insoluble tau at T181 in the LRRK2/TauP301L compared to TauP301L mice. Kawakami et al. [35] previously reported that LRRK2 did not promote phosphorylation of tau S199/S202/T205 in vitro and instead increased phosphorylation of T181 in cell culture and in vitro, a modification of tau that required the interaction with microtubules. Ujiie et al. [71] reported that LRRK2 modestly enhanced T181 phosphorylation in cell culture. The discrepancy between our findings and these reports may arise from differences between constructs or reaction design. Furthermore, the LRRK2/TauP301L mice express mutant tau, which has reduced tubulin binding [25, 27], potentially decreasing our ability to uncover tubulin-dependent LRRK2 phosphorylation of tau.

The evolution of toxic tau is a complex event, with no consensus on the biochemical switch from soluble to insoluble tau or functional to dysfunctional species. Our neuropathological analysis of LRRK2/TauP301L mice compared to TauP301L mice revealed elevated immunostaining with the MC1 antibody, which detects tau in an abnormal,
disease-relevant conformation [73], agreeing with our biochemical findings of increased 64 kDa sarkosyl-insoluble tau. Although our in vitro results suggest that the increase in tauopathy in the LRRK2/TauP301L mice is likely derived from the kinase function of LRRK2, it is possible that in vivo LRRK2 also promotes the aggregation of tau into the insoluble fraction by indirect cellular mechanisms. Other functions such as its regulation of autophagy have been assigned to LRRK2, which may contribute to our in vivo observations. In addition, some findings suggest that LRRK2-mediated tau phosphorylation can inhibit microtubule binding [35], which could also promote tau aggregation. Further studies will be required to determine the relative contribution of these alternative mechanisms on tau aggregation.

In some cases, we detected an influence of sex as well as genotype on neuropathological and biochemical outcomes in our mouse studies when assessed by two-way ANOVA. Neither transgenic tau nor LRRK2 expression was influenced by sex; therefore, these differences are not easily explained, but they are interesting and could be physiologically important. Curiously, the age-associated cumulative incidence of LRRK2 G2019S PD in Tunisia is gender specific—the median age of onset of female carriers being 5 years younger (in preparation, Matthew J. Farrer). In our lab, we have observed a non-significant trend that female rTg4510 mice have steeper exponential phase of tau pathology than male rTg4510 mice between ~4 and 6 months of age (personal communication, Jada Lewis). This inherent difference may be amplified by LRRK2 influence on tau pathology.

Our data, in aggregate, demonstrate that LRRK2 directly phosphorylates tau at T149 and T153 in vitro and the ability of LRRK2 to phosphorylate tau at these sites may underlie its ability to promote tauopathy in our novel mouse model. Our current in vivo studies are the first of their kind and provide compelling evidence that LRRK2 and tau interact in a disease-relevant manner. Further, the presence of phosphorylation at tau T149 and T153 in a variety of tau pathologies suggests that LRRK2 genetic studies in human tauopathies may be warranted.

Acknowledgments We would like to acknowledge support by NINDS (NIH 1F31NS078896-01-A1) to RMB, (R01NS065860) to HLM, (P50NS072187) to DWD, and (5R01NS082672) to JL and BIG. MJF acknowledges support through the Canada Excellence Research Chairs program and the Dr. Donald Rix BC Leadership Chair. This work also was funded by a grant from The Ellison Medical Foundation to BIG. Additional support was provided from the Mayo Clinic to HLM, MJF, DWD, and JL and the University of Florida Department of Neuroscience and Center for Translational Research in Neurodegenerative Disease to BIG and JL. LRRK2 screening was done by MJF and Owen Ross at the Mayo Clinic through support from the Udall Center (P50 NS72187). We would like to thank William S. Lane and the Harvard Mass Spectrometry and Proteomics Resource Laboratory (Cambridge, MA) for the mass spectrometry analyses. Clipart for Supplemental Figure 2 was obtained from http://www.biochem.wisc.edu/medialab/clipart.aspx.

Conflict of interest JL holds IP and has received royalties in excess of $10,000 in the past year from the rTg4510 mouse model.

Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

References

1. Anand VS, Reichling LJ, Lipinski K, Stochaj W, Duan W, Kelleher K, Pungalia P, Brown EL, Reinhart PH, Somberg R, Hirst WD, Riddle SM, Braithwaite SP (2009) Investigation of leucine-rich repeat kinase 2: enzymological properties and novel assays. FEBS J 276(2):466–478. doi:10.1111/j.1742-4658.2008.06789.x
2. Augustinack JC, Schneider A, Mandelkow EM, Hyman BT (2002) Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer’s disease. Acta Neuropathol 103(1):26–35
3. Biskup S, West AB (2009) Zeroing in on LRRK2-linked pathogenic mechanisms in Parkinson’s disease. Biochim Biophys Acta 1792(7):625–633. doi:10.1016/j.bbadis.2008.09.015
4. Chen CY, Weng YH, Chien KY, Lin KJ, Yeh TH, Cheng YP, Lu CS, Wang HL (2012) (G2019S) LRRK2 activates MKK4-JNK pathway and causes degeneration of SN dopaminergic neurons in a transgenic mouse model of PD. Cell Death Differ 19(10):1623–1633. doi:10.1038/cdd.2012.42
5. Chittum HS, Lane WS, Carlson BA, Roller PP, Lung FD, Lee BJ, Hatfield DL (1998) Rabbit beta-globin is extended beyond its UGA stop codon by multiple suppressions and translational reading gaps. Biochemistry 37(31):10866–10870. doi:10.1021/bi981042r
6. Cookson MR (2012) Cellular effects of LRRK2 mutations. Biochem Soc Trans 40(5):1070–1073. doi:BST20120165
7. Coppola G, Chinnathambi S, Lee JJ, Dombroski BA, Baker MC, Soto-Oortolaza AI, Lee SE, Klein E, Huang AY, Sears R, Lane JR, Karydas AM, Kenet RO, Biernt J, Wang LS, Cotman CW, Decarli CS, Levey AI, Ringman JM, Mendez MF, Chui HC, Le Ber I, Brice A, Lupton MK, Preza E, Lovestone S, Powell J, Graff-Radford N, Petersen RC, Boeve BF, Lippa CF, Bigio EH, Mackenzie I, Finger E, Kertesz A, Caselli RJ, Gearing M, Juncos JL, Gheiti B, Spina S, Bordelon YM, Tourtellotte WW, Frosch MP, Vonsattel JP, Zaro C, Beach TG, Albin RL, Lieberman AP, Lee VM, Trojanowski JQ, Van Deerlin VM, Bird TD, Galasko DR, Masliah E, White CL, Troncoso JC, Hannequin D, Boxer AL, Geschwind MD, Kumar S, Mandelkow EM, Wszolek ZK, Uitti RJ, Dickson DW, Haines JL, Mayeux R, Pieric-Vance MA, Farrer LA, Ross OA, Rademakers R, Schellenberg GD, Miller BL, Mandelkow E, Geschwind DH (2012) Evidence for a role of the rare p. A152T variant in MAPT in increasing the risk for FTD-spectrum and Alzheimer’s diseases. Hum Mol Genet 21(15):3500–3512. doi:10.1093/hmg/dds161
8. Covey JP, Giasson BI (2009) Identification of compounds that inhibit the kinase activity of leucine-rich repeat kinase 2. Biochem Biophys Res Commun 378(3):473–477. doi:10.1016/j.bbrc.2008.11.048
9. Covey JP, Giasson BI (2010) The G2019S pathogenic mutation disrupts sensitivity of leucine-rich repeat kinase 2 to
manganese kinase inhibition. J Neurochem 115(1):36–46. doi:10.1111/j.1471-4159.2010.06894.x

10. Covey JP, Yuan W, Waxman EA, Hurtig HI, Van Deerlin VM, Giasson BI (2009) Clinical features of patients with leucine-rich repeat kinase-2 mutations. Mov Disord 24(1):32–39. doi:10.1002/mds.22096

11. Crowe A, Ksiezak-Reding H, Liu WK, Dickson DW, Yen SH (1991) The N terminal region of human tau is present in Alzheimer’s disease protein A68 and is incorporated into paired helical filaments. Ann J Pathol 139(6):1463–1470

12. Dachsel JC, Farrer MJ (2010) LRRK2 and Parkinson disease. Arch Neurol 67(5):542–547. doi:10.1001/archneurol.2010.79

13. Davies P, Hinkle KM, Sukar NN, Sepulveda B, Mesias R, Serrano G, Alessi DR, Beach TG, Benson DL, White CL, Cowell RM, Das SS, West AB, Melrose HL (2013) Comprehensive characterization and optimization of anti-LRRK2 (leucine-rich repeat kinase 2) monoclonal antibodies. Biochem J 453(1):101–113. doi:10.1042/BJ20121742

14. Duda JE, Giasson BI, Mabon ME, Miller DC, Golbe LI, Lee VM, Trojanowski JQ (2002) Concordance of alpha-synuclein and tau brain pathology in the Contursi kindred. Acta Neuropathol 104(1):7–11. doi:10.1007/s00401-002-0563-3

15. Eng JK, Mccormack AL, Yates JR (1994) An approach to correlate tandem mass-spectral data of peptides with amino-acid-sequences in a protein database. J Am Soc Mass Spectr 5(11):976–989. doi:10.1007/BF00210915

16. Farrer MJ, Stone JT, Lin CH, Dachsel JC, Hulihan MM, Haugervoll K, Ross OA, Wu RM (2007) Lrrk2 G2385R is an ancestral risk factor for Parkinson’s disease in Asia. Parkinsonism Relat Disord 13(3):89–92. doi:S1353-8020(06)00287-2

17. Gaig C, Marti MJ, Ezquerra M, Rey MJ, Cardozo A, Tolosa E (2007) G2019S LRRK2 mutation causing Parkinson’s disease without Lewy bodies. J Neurol Neurosurg Psychiatry 78(6):626–628. doi:jnnp.2006.107904

18. Giasson BI, Covey JP, Bonini NM, Hurtig HI, Farrer MJ, Trojanowski JQ, Van Deerlin VM (2006) Biochemical and pathological characterization of Lrrk2. Ann Neurol 59(2):315–322. doi:10.1002/ana.20791

19. Giasson BI, Van Deerlin VM (2008) Mutations in LRRK2 as a cause of Parkinson’s disease. Neurosignals 16(1):99–105. doi:10.1042/BJ20070209

20. Gloeckner CJ, Schumacher A, Boldt K, Ueffing M (2009) The Parkinson disease-associated protein kinase LRRK2 exhibits MAPKKK activity and phosphorylates MKK3/6 and MKK4/7, in vitro. J Neurochem 109(4):959–968. doi:10.1111/j.1471-4159.2009.06024.x

21. Greggio E, Cookson MR (2009) Leucine-rich repeat kinase 2 mutations and Parkinson’s disease: three questions. ASN Neuro 1(1). doi:10.1042/AN20090007

22. Hanner DP, Anderton BH, Noble W (2009) Tau phosphorylation: the therapeutic challenge for neurodegenerative disease. Trends Mol Med 15(3):112–119. doi:10.1016/j.molmed.2009.01.003

23. Hanner DP, Byers HL, Wray S, Leung KY, Saxton MJ, Beer-eram A, Reynolds CH, Ward MA, Anderton BH (2007) Novel phosphorylation sites in tau from Alzheimer brain support a role for casemine kinase 1 in disease pathogenesis. J Biol Chem 282(32):23645–23654. doi:10.1074/jbc.M702692000

24. Hanner DP, Noble W (2011) Functional implications of glycogen synthase kinase-3-mediated tau phosphorylation. Int J Alzheimer’s Dis 2011:352805. doi:10.4061/2011/352805

25. Hasegawa M, Smith MJ, Goedert M (1998) Tau proteins with FTDP-17 mutations have a reduced ability to promote microtubule assembly. FEBS Lett 437(3):207–210. doi:10.1016/S0014-5793(98)01217-4

26. Haugervoll K, Wszolek ZK (2009) Clinical features of LRRK2 parkinsonism. Parkinsonism Relat Disord 15(Suppl 3):S205–S208. doi:10.1016/S1353-8020(09)70815-6

27. Hong M, Zhukareva V, Vogelsberg-Ragaglia V, Wszolek Z, Reed L, Miller BI, Geschwind DH, Bird TD, McKeel D, Goate A, Morris JC, Wilhelmsen KC, Schellenberg GD, Trojanowski JQ, Lee VM (1998) Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17. Science 282(5395):1914–1917

28. Hutton M, Lendon CL, Rizzu P, Baker M, Froehlich S, Houlden H, Pickering-Brown S, Chakraverty S, Isaacs A, Grover A, Hackett J, Adamson J, Lincoln S, Dickson D, Davies P, Petersen RC, Stevens M, de Graaff E, Wauters E, van Baren J, Hillebrand M, Joosse M, Kwon JM, Nowotny P, Che LK, Norton J, Morris JC, Reed LA, Trojanowski J, Basan H, Lannfelt L, Neysat M, Fahn S, Dark F, Tannenberg T, Dodd PR, Hayward N, Kwok JB, Schofield PR, Andreadis A, Snowden J, Craufurd D, Neary D, Owen F, Oostra BA, Hardy J, Goate A, van Swieten J, Mann D, Lynch T, Heutink P (1998) Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 393(6686):702–705. doi:10.1038/31508

29. Illenberger S, Zheng-Fischhofer Q, Preuss U, Stamer K, Bau mann K, Trinczek B, Biernat J, Godemann R, Mandelkow EM, Mandelkow E (1998) The endogenous and cell cycle-dependent phosphorylation of tau protein in living cells: implications for Alzheimer’s disease. Mol Biol Cell 9(6):1495–1512

30. Isihazawa T, Mattila P, Davies P, Wang D, Dickson DW (2003) Colocalization of tau and alpha-synuclein epitopes in Lewy bodies. J Neuropath Exp Neurol 62(4):389–397

31. Jaleel M, Nichols RJ, Deak M, Campbell DG, Gillardon F, Knebel A, Alessi DR (2007) LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson’s disease mutants affect kinase activity. Biochem J 405(2):307–317. doi:B120070209

32. Jellinger KA (2012) Neuropathology of sporadic Parkinson’s disease: evaluation and changes of concepts. Mov Disord 27(1):8–30. doi:10.1002/mds.23795

33. Kachergus J, Mata IF, Hulihan M, Taylor JP, Lincoln S, Aasly J, Gibson JM, Ross OA, Lynch T, Wiley J, Payami H, Nutt J, Marinagore DM, Czyzewski K, Styczynska M, Wszolek ZK, Farrer MJ, Toft M (2005) Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations. Am J Hum Genet 76(4):672–680. doi:S0002-9297(07)072878-X

34. Kara E, Ling H, Pittman AM, Shaw K, de Silva R, Simone R, Holton JL, Warren JD, Rohrer JD, Xiromerissiou G, Lees A, Hardy J, Houlden H, Revesz T (2012) The MAPT p.A152T variant is a risk factor associated with tauopathies with atypical clinical and neuropathological features. Neurobiol Aging 33(9):2223–2231 e2214. doi:10.1016/j.neurobiolaging.2012.04.006

35. Kawakami F, Yabata T, Ohta E, Maekawa T, Shimada N, Suzuki M, Maruyama H, Ichikawa T, Obata F (2012) LRRK2 phosphorylates tubulin-associated tau but not the free molecule: LRRK2-mediated regulation of the tau-tubulin association and neurite outgrowth. PLoS ONE 7(1):e30834. doi:10.1371/journal.pone.0030834

36. Kovacs GG, Wohrer A, Strobel T, Botond G, Attems J, Budka H (2011) Unclassifiable tauopathy associated with an A152T variation in MAPT exon 7. Clin Neuropathol 30(1):3–10. doi:10.1002/mds.23795

37. Lee J, Mcgowan E, Rockwood J, Melrose H, Nacharaju P, Van Slegtenhorst M, gwinn-Hardy K, Paul Murphy M, Baker M, Xu Y, Duff K, Hardy J, Corral A, Lin WL, Yen SH, Dickson
DW, Davies P, Hutton M (2000) Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat Genet 25(4):402–405. doi:10.1038/78078

40. Li X, Patel JC, Wang J, Avshalumov MV, Nicholson C, Buxbaum JD, Elder GA, Rice ME, Yue Z (2010) Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson’s disease mutation G2019S. J Neurosci 30(5):1788–1797. doi:10.1523/JNEUROSCI.5604-09.2010

41. Li Y, Liu W, Oo TF, Wang L, Tang Y, Jackson-Lewis V, Zhou C, Geggman K, Bogdanov M, Przedborski S, Beal MF, Burke RE, Li C (2009) Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson’s disease. Nat Neurosci 12(7):826–828. doi:10.1038/nn.2349

42. Lin CH, Tsai PI, Wu RM, Chien CT (2010) LRRK2 G2019S mutation induces dendrite degeneration through mislocalization and phosphorylation of tau by recruiting autoactivated GSK3α. J Neurosci 30(39):13138–13149. doi:10.1523/JNEUROSCI.1737-10.2010

43. Ling H, Kara E, Bandopadhyay R, Hardy J, Holton J, Xia, liang H, Kara E, Bandopadhyay R, Hardy J, Holton J, Xiromerisiou G, Lees A, Houlden H, Revesz T (2013) TDP-43 pathology in a patient carrying G2019S LRRK2 mutation and a novel p. Q124E MAPT. Neurobiol Aging. DOI: S0197-4580(13)00164-4

44. Liu AK, Leak RK, li l, Zigmond MJ (2008) Wild-type LRRK2 but not its mutant attenuates stress-induced cell death via ERK pathway. Neurobiol Dis 31(2):116–124. doi:10.1016/j.nbd.2008.06.016

45. Liu SJ, Zhang JY, Li HL, Fang ZY, Wang Q, Deng HM, Gong CX, Grundke-Iqbal I, Iqbal K, Wang JZ (2004) Tau becomes a more favorable substrate for GSK-3 when it is prephosphorylated by PKA in rat brain. J Biol Chem 279(48):50078–50088. doi:10.1074/jbc.M401609200

46. Melrose HL, Dachsel JC, Behrouz B, Lincoln SJ, Yue M, Hinkle KM, Kent CB, Korvatska E, Taylor JP, Witten L, Liang YQ, Beevers JE, Boules M, Dugger BN, Serna VA, Gauthaman A, Yu X, Castaneda-Casey M, Braithwaite AT, Ogholikhan S, Yu N, Bass D, Tyndall G, Schellenberg GD, Dickson DW, Janus C, Farrer MJ (2010) Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice. Neurobiol Dis 40(3):503–517. doi:10.1016/j.nbd.2010.07.010

47. Morris M, Maeda S, Vossel K, Mucke L (2011) The many faces of tau. Neuron 70(3):410–426. doi:10.1016/j.neuron.2011.04.009

48. Nichols RJ, Dzamko N, Hutti JE, Canley LC, Deak M, Moran J, Bamborough P, Reith AD, Alessi DR (2009) Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson’s disease. Biochem J 424(1):47–60. doi:10.1042/Bj20091035

49. Ohta E, Kawakami F, Kubo M, Obata F (2011) LRRK2 directly phosphorylates Akt1 as a possible physiological substrate: impairment of the kinase activity by Parkinson’s disease-associated mutations. FEBS Lett 585(14):2165–2170. doi:10.1016/j.febslet.2011.05.044

50. Okochi M, Walter J, Koyama A, Nakajo S, Baba M, Iwatsubo T, Meijer L, Kahle PJ, Haass C (2000) Constitutive phosphorylation of the Parkinson’s disease associated alpha-synuclein. J Biol Chem 275(1):390–397

51. Paisan-Ruiz C, Jain S, Evans EW,Gilks WP, Simon J, van der Brug M, Lopez de Munain A, Aparicio S, Gil AM, Khan N, Johnson J, Martinez JR, Nicholl D, Carrera IM, Pena AS, de Silva R, Lees A, Marti-Masso JF, Perez-Tur I, Wood NW, Singleton AB (2004) Cloning of the gene containing mutations that cause PARK8-linked Parkinson’s disease. Neuron 44(4):595–600. doi:10.1016/S0896-6273(04)00689-0

52. Paxinos GFK (2001) The mouse brain in stereotaxic coordinates, 2nd edn. Academic Press, San Diego
Forster C, Yue M, Orne J, Janus C, Mariash A, Kuskowski M, Hyman B, Hutton M, Ashe KH (2005) Tau suppression in a neurodegenerative mouse model improves memory function. Science 309(5733):476–481. doi:309/5733/476

66. Schneider A, Biernat J, von Bergen M, Mandelkow E, Mandelkow EM (1999) Phosphorylation that detaches tau protein from microtubules (Ser262, Ser214) also protects it against aggregation into Alzheimer paired helical filaments. Biochemistry 38(12):3549–3558. doi:10.1021/bi981874p

67. Smith WW, Pei Z, Jiang H, Dawson VL, Dawson TM, Ross CA (2006) Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat Neurosci 9(10):1231–1233. doi:nn1776

68. Spillantini MG, Goedert M (2013) Tau pathology and neurodegeneration. Lancet Neurol 12(6):609–622. doi:10.1016/S1474-4422(13)70090-5

69. Spillantini MG, Murrell Jr, Goedert M, Farlow MR, Klug A, Ghetti B (1998) Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc Natl Acad Sci USA 95(13):7737–7741

70. Steinhilb ML, Dias-Santagata D, Fulga TA, Felch DL, Feany MB (2007) Tau phosphorylation sites work in concert to promote neurotoxicity in vivo. Mol Biol Cell 18(12):5060–5068. doi:E07-04-0327

71. Ujje S, Hatano T, Kubo S, Imai S, Sato S, Uchihara T, Yagishita S, Hasegawa K, Kowa H, Sakai F, Hattori N (2012) LRRK2 I2020T mutation is associated with tau pathology. Parkinsonism Relat Disord 18(7):819–823. doi:10.1016/j.parkrel.2012.03.024

72. Waxman A, Covy JP, Bukh I, Li X, Dawson TM, Gias- son BI (2009) Leucine-rich repeat kinase 2 expression leads to aggresome formation that is not associated with alpha-synuclein inclusions. J Neuropathol Exp Neurol 68(7):785–796. doi:10.1097/NEN.0b013e3181aa4ff6d

73. Weaver CL, Espinoza M, Kress Y, Davies P (2000) Conformational change as one of the earliest alterations of tau in Alzheimer’s disease. Neurobiol Aging 21(5):719–727. doi:S0197-4580(00)00157-3

74. West AB, Moore DJ, Biskup S, Bugayenko A, Smith WW, Ross CA, Dawson VL, Dawson TM (2005) Parkinson’s disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci USA 102(46):16842–16847. doi:0507360102

75. Wszolek ZK, Pfeiffer RF, Tsuboi Y, Uitti RJ, McComb RD, Stoessl AJ, Stromgosky AJ, Zimprich A, Muller-Myhsok B, Farrer MJ, Gasser T, Calne DB, Dickson DW (2004) Autosomal dominant parkinsonism associated with variable synuclein and tau pathology. Neurology 62(9):1619–1622

76. Zach S, Felk S, Gillardon F (2010) Signal transduction protein array analysis links LRRK2 to Ste20 kinases and PKC zeta that modulate neuronal plasticity. PLoS ONE 5(10):e13191. doi:10.1371/journal.pone.0013191

77. Zheng-Fischhofer Q, Biernat J, Mandelkow EM, Illenberger S, Godemann R, Mandelkow E (1998) Sequential phosphorylation of Tau by glycogen synthase kinase-3beta and protein kinase A at Thr212 and Ser214 generates the Alzheimer-specific epitope of antibody AT100 and requires a paired-helical-filament-like conformation. Eur J Biochem 252(3):542–552

78. Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S, Kachergus J, Hulihan M, Uitti RJ, Calne DB, Stoessl AJ, Pfeiffer RF, Patenge N, Carbajal IC, Vieregge P, Asmus F, Muller-Myh- sok B, Dickson DW, Meitinger T, Strom TM, Wszolek ZK, Gasser T (2004) Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44(4):601–607. doi:S0896627304007202